Maria Concetta Postorino1, Filippo Luciani2, Carmelo Mangano3, Maria Stella Carpentieri3, Paolo Scerbo4, Armando Priamo4, Giuseppina Berardelli5, Roberto Marino6, Alfredo Vallone6, Nicola Serrao7, Vincenzo Pisani1, Chiara Costa1, Albano Terremoto2, Giuseppe Foti3, Lucio Cosco4, Massimo Calderazzo5, Domenico Corigliano5, Preziosa Scordo1, Alessio Strazzulla1, Carlo Torti1 and the CalabrHIV Study Group
Diseases Unit, “Magna Graecia” University, Catanzaro
2Infectious Diseases Unit, “Annunziata” Hospital, Cosenza
3Infectious Diseases Unit, “Bianchi-Melacrino-Morelli” Hospital, Reggio Calabria
4Infectious Diseases Unit, “Pugliese-Ciaccio” Hospital, Catanzaro
5Infectious Diseases Unit, “Giovanni Paolo II” Hospital, LameziaTerme, Catanzaro
6Infectious Diseases Unit, “Jazzolino” Hospital, Vibo Valentia
7Infectious Diseases Unit, “San Giovanni di Dio” Hospital, Crotone
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background and Objectives: HIV epidemics may differ among epidemiological contexts. We aimed at constructing an HIV clinical cohort whose main epidemiological, clinical and therapeutical characteristics are described (the CalabrHIV cohort, Calabria Region, Southern Italy).
Methods: The CalabrHIV Cohort includes all HIV patients on active follow-up in all infectious disease centers in the Calabria Region as at October 2014. All information was recorded in a common electronic database. Not-infectious co-morbidities (such as cardiovascular diseases, bone fractures, diabetes, renal failure and hypertension) were also studied.
Results: 548 patients (68% males; 59% aged <50 years) were included in the CalabrHIV cohort. Major risk factors were: sexual transmission (49%) and intravenous drug use (34%). 39% patients had HCV and/or HBV co-infection. Amongst 404 patients who had a complete clinical history, 34% were AIDS presenters and 49.3% had CD4 count ≤350/mm3 at HIV diagnosis. 83% patients on HAART had undetectable HIV-RNA. Hypertension was the most frequent co-morbidity (21.5%). Multimorbidity was more frequent in >50 years old patients than in <50 years old ones (30% vs. 6%; p<0.0001). Co-morbidity was more frequent in HCV and/or HBV co-infected than in HIV mono-infected patients (46.6% vs. 31.7%: p=0.0006).
Conclusion: This cohort presentation study sheds light, for the first time, on HIV patients’ characteristics in the Calabria Region. We showed that HIV-infected patients with chronic hepatitis were affected by concomitant not-infectious co-morbidities more than the HIV mono-infected individuals. New HCV treatments are therefore to be implemented in the co-infected population.
HIV infection may give diverse clinical manifestations, due to
virus-related factors, but also to host-related conditions and
psycho-social peculiarities. Therefore, epidemiological and clinical
features of HIV-infected patients may be different across different
countries and regions of the same country, so detailed regional
analyzes are very important to identify health priorities of HIV
Percentages of patients with HIV infection and/or with AIDS have been underrated in the Calabria Region. Major causes may be hypothesized: stigma and marginalization due to HIV diagnosis, the psycho-social fragility of HIV population, under-reporting of new HIV diagnoses. Moreover, in the Calabria Region, incidence, prevalence and characteristics of diseases (including HIV) are affected by a massive “health migration”. Indeed, for a matter of reasons, many patients living in the Calabria Region choose to be followed in Hospitals located in the North and Centre of Italy.
In HIV patients also drug prescription can diverge from national guidelines on regional clinical practice. Moreover, there are no available data regarding premature aging and not-infective co-morbidities in HIV-infected patients from the Calabria region.
So, the aim of this study was to describe baseline characteristics of HIV population in active follow-up in the Calabria Region, in order to identify health priorities of patients and create a large regional prospective cohort including all HIV-infected patients (the CalabrHIV Cohort). Main epidemiological, clinical and therapeutical characteristics have been assessed for the first time in our region. Moreover, we wanted to explore in HIV-infected patients whether or not HCV or HBV co-infection was associated with higher percentages of not-infectious co- morbidities than HIV mono-infection.
Both HIV and HCV are associated with a wide range of co-morbidities.[4-7] In particular, HIV-infected patients suffer from premature aging, putting them at risk of not-infectious co-morbidities at younger ages than the general population.[3,4] Indeed, high levels of predictive biomarkers of inflammation typical of the great elderly people were found in young people with HIV infection. Previous cohort studies showed a greater risk of diabetes mellitus, acute myocardial infarction and cerebrovascular events in HIV-infected patients than in HIV-negative ones.[8-12] It is currently not demonstrated whether HCV or HBV co-infection may accelerate premature aging in HIV-infected patients, increasing rates of cardiovascular, metabolic and renal diseases in these subjects. In conclusion, the reasons leading to the study were:
1. To present a cohort profile of the CalabrHIV study group.
2. To focus on clinical characteristics of the enrolled patients, mainly the risk of comorbidities.
Materials and methods
All the infectious
diseases centers in the Calabria Region (Catanzaro, Vibo Valentia,
Reggio Calabria, Cosenza, and Crotone) have merged their data to create
a regional observational prospective cohort, so called CalabrHIV
Cohort. Patients’ characteristics were collected in a common electronic
database containing all epidemiological, demographic, virological,
immunological, clinical and therapeutic information. Latest follow-up
was available in October 2014.
Not-infectious comorbidities diagnosed until October 2014 were also recorded: cardiovascular diseases (defined as acute myocardial infarction, stroke, transient ischemic attack, angina pectoris, coronary bypass, angioplasty, chronic occlusive arterial disease), hypertension (defined as blood pressure ≥140/90 mmHg or antihypertensive therapy), diabetes (fasting serum glucose ≥126 mg/dl or anti-diabetes therapy), renal failure (eGFR ≤60ml/min measured with CKD-EPI formula) and bone fractures. Multimorbidity was defined as ≥2 not-infectious co-morbidities occurring in the same patient. For the analysis of not-infectious co-morbidities, patients were divided into four age groups: aged ≤40, between 41 and 50 years, between 51 and 60 years and >60 years.
Data were analyzed using common statistical descriptive procedures (with statistical significance: p≤0.05).
Five hundred forty-eight patients (68% males; 59% aged <50 years) on active follow-up as at October 2014 were included in the CalabrHIV Cohort. Table 1 reports the main patients’ demographic, epidemiological and clinical characteristics. Major risk factors for HIV acquisition were sexual transmission (49%) and intravenous drug use (34%). About 40% patients had HCV and/or HBV co-infection.
|Table 1. Patient’ characteristics.|
and late presentation:
Although a good virological response was ongoing (73% had undetectable
HIV-RNA), the immunological status of patients, with a CD4 nadir
was still compromised. Only 42% of these patients had actual CD4 count
404/548 patients had available data about AIDS at HIV diagnosis, of
these 34% were AIDS presenters, and 49.3% had CD4 count ≤350/mm3.
HAART prescription: 90% patients were on HAART and, among these, 83% had undetectable HIV-RNA. A huge diversity in HAART prescription was noticed: 92% first-line HAART included ≥3 different drugs. Only 5% first line prescriptions included <3 antiretroviral drugs but, amongst the currently ongoing regimens, 15% included <3 drugs as simplification regimens. 49% patients actually in mono-/ dual- therapy vs. 40% patients actually in HAART had a nadir CD4 <200/mm3. Actual HIV RNA was <50 copies/ml in 81% patients receiving mono-/ dual- therapy and in 83% of patients on HAART. The actual CD4 T cell count was >500/mm3 in 60% patients receiving mono-/ dual- therapy and in 62% patients on HAART.
Study of not infectious co-morbidities: Median value of not infectious comorbidities per patient was 0.58 (range 0-4). 21.5% patients had at least one co-morbidity. None of the patients had five, not infectious comorbidities. Hypertension was the most frequent disease (21.5% patients) followed by cardiovascular diseases (11.5%), renal failure (10%) and diabetes (10%) (Figure 1). Multimorbidity was more frequently found higher in >50 years old patients than in <50 years old (30% vs. 6%; p<0.0001) (Figure 2).
|Figure 1. Not-infectious co-morbidities (%) by age classes|
|Figure 2. Multi-morbidity (% by age classes) in CalabrHIV cohort.|
were ranked into two groups: HIV mono-infected patients
(61%) and HIV patients co-infected with HCV and/or HBV (39%).
Table 2 shows main epidemiological, clinical and demographic characteristics of HIV mono-infected patients and HIV patients coinfected with HCV and/or HBV. Co-infected patients were significantly older [mean age 49 years (SD 8.7) vs. 46 years (SD 12.7); p=0.0003] and more frequently had AIDS than mono-infected ones (39% vs. 21%; p<0.0001). Although not statistically significant, nadir and actual CD4 T cell values were lower in co-infected patients than in mono-infected ones.
Multimorbidity rate was higher in patients aged ≥50 years with HCV and/or HBV co-infection than in HIV-mono-infected (70% vs. 46%; p=0.0037). An increased significance in the difference due to multimorbidity was found in age groups starting from 40 years (39.5% vs. 26%; p=0.0293), although difference was even inverse at >60 years of age (54% vs. 92%; p=0.026) (Figure 3a-b). There was a difference in bone fractures rates between HIV mono-infected patients and patients with HCV and/or HBV co-infection at a borderline significance value (5.2% vs. 9%; p=0.07).
|Table 2. Patients’ characteristics (HIV positive patients vs.HIV patients co-infected with viral hepatitis).|
|Figure 3. a) % Multi-morbidity in HIV mono infected patients; b) % Multi-morbidity in HIV patients co-infected with viral hepatitis|
In addition to the authors of this paper, CalabrHIV Cohort thanks all patients, doctors, nurses and colla+
\borators of all participating centers: Infectious Diseases Unit, “Magna Graecia” University, Catanzaro; Infectious Diseases Unit, “Annunziata” Hospital, Cosenza; Infectious Diseases Unit, “Bianchi-Melacrino-Morelli” Hospital, Reggio Calabria; Infectious Diseases Unit, “Pugliese-Ciaccio” Hospital, Catanzaro, Infectious Diseases Unit, “Giovanni Paolo II” Hospital, LameziaTerme, Catanzaro, Infectious Diseases Unit, “Jazzolino” Hospital, Vibo Valentia, Infectious Diseases Unit, “San Giovanni di Dio” Hospital, Crotone.